CompletedNCT00191880
Atomoxetine and academic outcomes in children ages 8–11 with ADHD
About this title
Read the official source — NCT00191880Medication studyAges 8–11Canada
Understand this study
Who was this study for?
Listed age limits: 8 years to 11 years.
- Listed locations
- Calgary and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 100
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Canada
- Age range
- From 8 Years to 11 Years
- Official registry ID
- NCT00191880
- Official title
Show the full official title
A Phase IIIb Open-Label Trial of Atomoxetine Hydrochloride to Evaluate Academic Outcome in Children Ages 8 to 11 Years With Attention-Deficit/Hyperactivity Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Calgary · Edmonton · London
5 more locations
- Montreal
- Saskatoon
- Scarborough
- St. Johns
- Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including atomoxetine.
Who was this study for?
Listed age limits: 8 years to 11 years.
